Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma

Authors: Jia-Jia Huang, Ya-Jun Li, Yi Xia, Yu Wang, Wen-Xiao Wei, Ying-Jie Zhu, Tong-Yu Lin, Hui-Qiang Huang, Wen-Qi Jiang, Zhi-Ming Li

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Extranodal natural killer/T-cell lymphoma (ENKL) has heterogeneous clinical manifestations and prognosis. This study aims to evaluate the prognostic impact of absolute monocyte count (AMC) in ENKL, and provide some immunologically relevant information for better risk stratification in patients with ENKL.

Methods

Retrospective data from 163 patients newly diagnosed with ENKL were analyzed. The absolute monocyte count (AMC) at diagnosis was analyzed as continuous and dichotomized variables. Independent prognostic factors of survival were determined by Cox regression analysis.

Results

The AMC at diagnosis were related to overall survival (OS) and progression-free survival (PFS) in patients with ENKL. Multivariate analysis identified AMC as independent prognostic factors of survival, independent of International Prognostic Index (IPI) and Korean prognostic index (KPI). The prognostic index incorporating AMC and absolute lymphocyte count (ALC), another surrogate factor of immune status, could be used to stratify all 163 patients with ENKL into different prognostic groups. For patients who received chemotherapy followed by radiotherapy (102 cases), the three AMC/ALC index categories identified patients with significantly different survivals. When superimposed on IPI or KPI categories, the AMC/ALC index was better able to identify high-risk patients in the low-risk IPI or KPI category.

Conclusion

The baseline peripheral monocyte count is shown to be an effective prognostic indicator of survival in ENKL patients. The prognostic index related to tumor microenvironment might be helpful to identify high-risk patients with ENKL.
Appendix
Available only for authorised users
Literature
1.
Jaccard A, Hermine O: Extranodal natural killer/T-cell lymphoma: advances in the management. Curr Opin Oncol. 2011, 23: 429-435. 10.1097/CCO.0b013e328349aba6.CrossRefPubMed
2.
Liang X, Graham DK: Natural killer cell neoplasms. Cancer. 2008, 112: 1425-1436. 10.1002/cncr.23316.CrossRefPubMed
3.
Gill H, Liang RH, Tse E: Extranodal natural-killer/t-cell lymphoma, nasal type. Adv Hematol. 2010, 201: 627401-
4.
Gualco G, Domeny-Duarte P, Chioato L, Barber G, Natkunam Y, Bacchi CE: Clinicopathologic and molecular features of 122 Brazilian cases of nodal and extranodal NK/T-cell lymphoma, nasal type, with EBV subtyping analysis. Am J Surg Pathol. 2011, 35: 1195-1203. 10.1097/PAS.0b013e31821ec4b5.CrossRefPubMed
5.
Yang QP, Zhang WY, Yu JB, Zhao S, Xu H, Wang WY, Bi CF, Zuo Z, Wang XQ, Huang J, Dai L, Liu WP: Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011, 6: 77-10.1186/1746-1596-6-77.CrossRefPubMedPubMedCentral
6.
Li ZM, Zhu YJ, Sun J, Xia Y, Huang JJ, Zou BY, Lin TY, Huang HQ, Jiang WQ: Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma. Ann Hematol. 2012, 91: 1265-1270. 10.1007/s00277-012-1434-1.CrossRefPubMed
7.
Wang ZY, Li YX, Wang H, Wang WH, Jin J, Liu YP, Song YW, Wang SL, Liu XF, Yu ZH: Unfavorable prognosis of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma. Ann Oncol. 2011, 22: 390-396. 10.1093/annonc/mdq347.CrossRefPubMed
8.
Huang JJ, Zhu YJ, Xia Y, Zhao W, Lin TY, Jiang WQ, Huang HQ, Li ZM: A novel prognostic model for extranodal natural killer/T-cell lymphoma. Med Oncol. 2012, 29: 2183-2190. 10.1007/s12032-011-0030-x.CrossRefPubMed
9.
de Leval L, Gaulard P: Pathology and biology of peripheral T-cell lymphomas. Histopathology. 2011, 58: 49-68. 10.1111/j.1365-2559.2010.03704.x.CrossRefPubMed
10.
Ham MF, Ko YH: Natural killer cell neoplasm: biology and pathology. Int J Hematol. 2010, 92: 681-689. 10.1007/s12185-010-0738-y.CrossRefPubMed
11.
Li YX, Fang H, Liu QF, Lu J, Qi SN, Wang H, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Feng XL, Yu ZH: Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of waldeyer ring. Blood. 2008, 112: 3057-3064. 10.1182/blood-2008-05-160176.CrossRefPubMed
12.
Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS: Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006, 24: 612-618. 10.1200/JCO.2005.04.1384.CrossRefPubMed
13.
Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB: Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood. 2011, 117: 872-881. 10.1182/blood-2010-05-283820.CrossRefPubMedPubMedCentral
14.
Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK: Immunodeficiency-associated lymphomas. Blood Rev. 2008, 22: 261-281. 10.1016/j.blre.2008.03.009.CrossRefPubMed
15.
Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008, 359: 2313-2323. 10.1056/NEJMoa0802885.CrossRefPubMed
16.
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004, 351: 2159-2169. 10.1056/NEJMoa041869.CrossRefPubMed
17.
Steidl C, Gascoyne RD: The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011, 118: 2659-2669. 10.1182/blood-2011-05-326538.CrossRefPubMed
18.
De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA: Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer. 2008, 112: 407-415. 10.1002/cncr.23168.CrossRefPubMed
19.
Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ, Li ZM: Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol. 2011, 22: 149-155. 10.1093/annonc/mdq314.CrossRefPubMed
20.
Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, Song HS, Chung JS, Hyun MS, Sohn SK: Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia. 2007, 21: 2227-2230. 10.1038/sj.leu.2404780.CrossRefPubMed
21.
Kim YR, Kim JS, Kim SJ, Jung HA, Kim SJ, Kim WS, Lee HW, Eom HS, Jeong SH, Park JS, Cheong JW, Min YH: Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. J Hematol Oncol. 2011, 4: 34-10.1186/1756-8722-4-34.CrossRefPubMedPubMedCentral
22.
Porrata LF, Ristow K, Witzig TE, Tuinistra N, Habermann TM, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Markovic SN: Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas. Leukemia. 2007, 21: 2554-2556. 10.1038/sj.leu.2404819.CrossRefPubMed
23.
Wilcox RA, Wada DA, Ziesmer SC, Elsawa SF, Comfere NI, Dietz AB, Novak AJ, Witzig TE, Feldman AL, Pittelkow MR, Ansell SM: Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood. 2009, 114: 2936-2944. 10.1182/blood-2009-05-220111.CrossRefPubMedPubMedCentral
24.
Ishii H, Takahara M, Nagato T, Kis LL, Nagy N, Kishibe K, Harabuchi Y, Klein E: Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15. Int J Cancer. 2012, 130: 48-58. 10.1002/ijc.25969.CrossRefPubMed
25.
Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L: The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011, 25: 1502-1509. 10.1038/leu.2011.112.CrossRefPubMed
26.
Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L: The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma. 2012, 53: 575-580. 10.3109/10428194.2011.637211.CrossRefPubMed
27.
Kim TM, Heo DS: Extranodal NK/T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci. 2009, 100: 2242-2248. 10.1111/j.1349-7006.2009.01319.x.CrossRefPubMed
28.
Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM: The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007, 109: 1857-1861. 10.1182/blood-2006-08-038257.CrossRefPubMed
29.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol. 2007, 25: 579-586. 10.1200/JCO.2006.09.2403.CrossRefPubMed
30.
Grulich AE, Vajdic CM: The epidemiology of non-Hodgkin lymphoma. Pathology. 2005, 37: 409-419. 10.1080/00313020500370192.CrossRefPubMed
31.
Smedby KE, Hjalgrim H: Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011, 21: 293-298. 10.1016/j.semcancer.2011.09.010.CrossRefPubMed
32.
Jacobson CA, LaCasce AS: Lymphoma: risk and response after solid organ transplant. Oncology (Williston Park). 2011, 24: 936-944.
33.
Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S, Severson RK, Colt JS, Vasef MA, Rothman N, Blair A, Bernstein L, Cross AJ, De Roos AJ, Engels EA, Hein DW, Hill DA, Kelemen LE, Lim U, Lynch CF, Schenk M, Wacholder S, Ward MH, Hoar Zahm S, Chanock SJ, Cerhan JR, Hartge P: Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood. 2008, 112: 5150-5160. 10.1182/blood-2008-01-133587.CrossRefPubMedPubMedCentral
34.
Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, von der Maase H: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005, 93: 273-278. 10.1038/sj.bjc.6602702.CrossRefPubMedPubMedCentral
35.
Lopez-Gonzalez JS, Avila-Moreno F, Prado-Garcia H, Aguilar-Cazares D, Mandoki JJ, Meneses-Flores M: Lung carcinomas decrease the number of monocytes/macrophages (CD14+ cells) that produce TNF-alpha. Clin Immunol. 2007, 122: 323-329. 10.1016/j.clim.2006.11.003.CrossRefPubMed
36.
Hase S, Weinitschke K, Fischer K, Fornara P, Hoda R, Unverzagt S, Seliger B, Riemann D: Monitoring peri-operative immune suppression in renal cancer patients. Oncol Rep. 2011, 25: 1455-1464.PubMed
37.
Donskov F, von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006, 24: 1997-2005. 10.1200/JCO.2005.03.9594.CrossRefPubMed
38.
Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S: Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007, 179: 977-983.CrossRefPubMed
39.
Miyauchi K, Urano E, Yoshiyama H, Komano J: Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma. Cancer Sci. 2011, 102: 1236-1241. 10.1111/j.1349-7006.2011.01924.x.CrossRefPubMed
40.
Moriai S, Takahara M, Ogino T, Nagato T, Kishibe K, Ishii H, Katayama A, Shimizu N, Harabuchi Y: Production of interferon-{gamma}-inducible protein-10 and its role as an autocrine invasion factor in nasal natural killer/T-cell lymphoma cells. Clin Cancer Res. 2009, 15: 6771-6779. 10.1158/1078-0432.CCR-09-1052.CrossRefPubMed
41.
Nourse JP, Jones K, Gandhi MK: Epstein-Barr virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transplant. 2011, 11: 888-895. 10.1111/j.1600-6143.2011.03499.x.CrossRefPubMed
42.
Datta S, Sarvetnick N: Lymphocyte proliferation in immune-mediated diseases. Trends Immunol. 2009, 30: 430-438. 10.1016/j.it.2009.06.002.CrossRefPubMed
43.
Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K, Kanda Y, Hirokawa M, Kawabata Y, Matsumura T, Kusumi E, Hirabayashi N, Nagafuji K, Suzuki R, Takeuchi K, Oshimi K: Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol. 2005, 130: 561-567. 10.1111/j.1365-2141.2005.05651.x.CrossRefPubMed
44.
Suzuki R, Suzumiya J, Nakamura S, Kagami Y, Kameoka JI, Sakai C, Mukai H, Takenaka K, Yoshino T, Tsuzuki T, Sugimori H, Kawa K, Kodera Y, Oshimi K, NK-cell Tumor Study Group: Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant. 2006, 37: 425-431. 10.1038/sj.bmt.1705244.CrossRefPubMed
45.
Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J, Sakai C, Oshimi K, Kwong YL, Liang R, Yiu H, Wong KH, Cheng HC, Ryoo BY, Suh C, Ko YH, Kim K, Lee JW, Kim WS, Suzuki R: Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008, 14: 1356-1364. 10.1016/j.bbmt.2008.09.014.CrossRefPubMed
Metadata
Title
Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma
Authors
Jia-Jia Huang
Ya-Jun Li
Yi Xia
Yu Wang
Wen-Xiao Wei
Ying-Jie Zhu
Tong-Yu Lin
Hui-Qiang Huang
Wen-Qi Jiang
Zhi-Ming Li
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-222

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer

Research article

Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases

Research article

Annual Papanicolaou screening for 5 years among human papillomavirus-negative women

Research article

Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer

Research article

Colon cancer cells adopt an invasive phenotype without mesenchymal transition in 3-D but not 2-D culture upon combined stimulation with EGF and crypt growth factors

Research article

Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits